[HTML][HTML] Patient-derived xenograft (PDX) models, applications and challenges in cancer research
S Abdolahi, Z Ghazvinian, S Muhammadnejad… - Journal of Translational …, 2022 - Springer
The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …
[HTML][HTML] Humanized mouse model: a review on preclinical applications for cancer immunotherapy
L Yin, XJ Wang, DX Chen, XN Liu… - American journal of …, 2020 - ncbi.nlm.nih.gov
Due to the refractory and partial sensitive treatments to malignant cancers, immunotherapy
has increasingly become a hotspot in effective anti-tumor research. However, at present …
has increasingly become a hotspot in effective anti-tumor research. However, at present …
[HTML][HTML] Humanized mouse models to evaluate cancer immunotherapeutics
S Guil-Luna, C Sedlik, E Piaggio - Annual Review of Cancer …, 2021 - annualreviews.org
Immunotherapy is at the forefront of cancer treatment. The advent of numerous novel
approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive …
approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive …
[HTML][HTML] The multi-dimensional biomarker landscape in cancer immunotherapy
The field of immuno-oncology is now at the forefront of cancer care and is rapidly evolving.
The immune checkpoint blockade has been demonstrated to restore antitumor responses in …
The immune checkpoint blockade has been demonstrated to restore antitumor responses in …
[HTML][HTML] Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
M Zeng, Z Ruan, J Tang, M Liu, C Hu, P Fan… - Cancer Cell …, 2023 - Springer
Establishing appropriate preclinical models is essential for cancer research. Evidence
suggests that cancer is a highly heterogeneous disease. This follows the growing use of …
suggests that cancer is a highly heterogeneous disease. This follows the growing use of …
[HTML][HTML] Generation of orthotopic patient-derived xenografts in humanized mice for evaluation of emerging targeted therapies and immunotherapy combinations for …
Simple Summary Patient-derived xenografts (PDX) are valuable models in preclinical
oncology drug development. However, they are not well suited for testing immune-based …
oncology drug development. However, they are not well suited for testing immune-based …
[HTML][HTML] Modeling the tumor microenvironment and cancer immunotherapy in next-generation humanized mice
A Chen, I Neuwirth, D Herndler-Brandstetter - Cancers, 2023 - mdpi.com
Simple Summary A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …
Advancements in melanoma cancer metastasis models
LM Nascentes Melo, S Kumar, V Riess… - Pigment cell & …, 2023 - Wiley Online Library
Metastatic melanoma is a complex and deadly disease. Due to its complexity, the
development of novel therapeutic strategies to inhibit metastatic melanoma remains an …
development of novel therapeutic strategies to inhibit metastatic melanoma remains an …
[HTML][HTML] Combination of multiple omics techniques for a personalized therapy or treatment selection
C Massa, B Seliger - Frontiers in Immunology, 2023 - frontiersin.org
Despite targeted therapies and immunotherapies have revolutionized the treatment of
cancer patients, only a limited number of patients have long-term responses. Moreover, due …
cancer patients, only a limited number of patients have long-term responses. Moreover, due …
[HTML][HTML] Intussusceptive angiogenesis in human metastatic malignant melanoma
A Pandita, M Ekstrand, S Bjursten, Z Zhao… - The American Journal of …, 2021 - Elsevier
Angiogenesis supplies oxygen and nutrients to growing tumors. Inhibiting angiogenesis may
stop tumor growth, but vascular endothelial growth factor inhibitors have limited effect in …
stop tumor growth, but vascular endothelial growth factor inhibitors have limited effect in …